High Dose Insulin Therapy to Improve Liver Function
Status:
Unknown status
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
Insulin resistance is one of the key factors in defining a progressive course of chronic
Hepatitis C virus (HCV) infection and hepatic fibrosis. Multiple trials have targeted insulin
resistance as an adjuvant way to manage hepatitis C liver disease with promising results.
Long term therapy using high dose insulin was shown to significantly reduce insulin
resistance in obese patients. In cardiac and critically ill patients, long term insulin was
shown to produce better outcomes mainly by reducing the overt inflammatory response.
Furthermore, initial results of ongoing trials are revealing more benefits of insulin
therapy. Using the (hyperinsulinimic normoglycemic clamp) for eight hours on patients
undergoing major liver resection was able to maximize their liver function post-operatively.
This trial also demonstrated inhibition of the inflammatory response, improvement in liver
glycogen, inhibition of apoptosis and stimulation of liver regeneration.
Putting in mind the potential ability of the liver to regenerate and regain better function.
The anti-inflammatory properties of insulin therapy along with its ability to reduce insulin
resistance over time has led us to see the potential benefits of using insulin therapy on
patients with chronic hepatitis C virus liver cirrhosis. Insulin will target the
pathophysiology of the disease at a cellular and a molecular level.
The investigators theorize that long-term high insulin therapy would be able to promote
better liver function and slow down fibrosis and injury in this population of patients.
Phase:
N/A
Details
Lead Sponsor:
McGill University Health Center McGill University Health Centre/Research Institute of the McGill University Health Centre